| Similar Articles |
|---|
 |
Bio-IT World
November 19, 2004
Hoffer & Nambiar |
Mirus Index Heads South Overall, companies in the Mirus Index declined in the third quarter of 2004.   |
Bio-IT World
November 14, 2003
Hoffer et al. |
Over the Rainbow Yet? Consolidation slows, valuations grow, and now there's hope for some biotech IPOs. |
Bio-IT World
February 18, 2004 |
On the Up and Up Market values for biotec companies increase as they deal and deliver in the fourth quarter |
Bio-IT World
August 18, 2004 |
Little News Is Good News Hopes that a burst of high-flying IPOs would fan investor interest in biotechnology were dashed in Q2, as several companies had to accept much lower prices than anticipated. |
Bio-IT World
August 13, 2003
Branca et al. |
Discovery Surges and Tools Deliver Market Compass for Q2 finds consolidation among drug discovery companies continuing, but market caps rising. |
Bio-IT World
January 13, 2003
Malorye Branca |
Charting a Course After the Genome A quarterly feature looks at the financial numbers in the bio-IT industry. |
Bio-IT World
May 2006
G. Steven Burrill |
Biotech Turns in Mixed Q1 Performance Biotech closed out a rough month of March, but this did not take the shine off the exceptional performance of the mid- and small-cap biotech companies. |
Inc.
May 1, 2002
Kenneth Klee |
The Industry You Can't Afford to Miss After more than two decades of hype, hope, disappointment, and progress, the hundreds of mostly small, money-burning companies that make up the biotech industry are experiencing a decisive shift in their relationship with the giant, rich pharmaceutical companies... |
Bio-IT World
May 9, 2003
Malorye Branca |
Discovering the Joy of Cannibalism Persistent financial pressures feed continuing consolidation among struggling genomics companies |
Bio-IT World
August 2005
G. Steven Burrill |
Biotech Outperforms Market in Q2 Heading into the summer, biotech widely outperformed the Dow and Nasdaq on a year-to-date basis. But the positive performance is attributable to a mere handful of companies driving the market. |
The Motley Fool
December 14, 2004
Charly Travers |
Genetics of a Rule Breaker Investing is a lifelong learning process. We never know everything, but it is important we strive to learn from the lumps we take along the way. Here are some hard-earned tips from a biotech investor. |
The Motley Fool
January 25, 2005
Charly Travers |
Grading Old-School Biotech Be very wary of biotech IPOs from companies lacking drugs. |
BusinessWeek
June 13, 2005
Arlene Weintraub |
Why Biotech Stocks Are Sedated Biotech might seem like a can't-miss investing opportunity but many investors are taking a pass on biotech, even amid bona fide scientific advances. |
Pharmaceutical Executive
November 1, 2011 |
Turbulent Waters: M&As 2011 The latest numbers in pharma deals reveals a sector in transition, where market volatility has sharply degraded the appetite for risk. |
The Motley Fool
August 5, 2011
Brian Orelli |
Still Want to Be the Next Dendreon? The biotech market is punished. |
The Motley Fool
March 4, 2004
Brian Gorman |
Biotech Is Back Biotech financing is on a roll. But before you jump into the sector, learn some lessons from the past. Companies that enter the market earlier in the boom are better positioned than those that start later, and it's best to choose firms with late-stage drug candidates. |
The Motley Fool
April 9, 2010
Brian Orelli |
Double Your Biotech Returns! Really! Taking a closer look at leveraged biotech ETFs. |
The Motley Fool
July 30, 2004
Roger Nusbaum |
Gilead Keeps Rolling Along Biotech can be a tough place to invest, but Gilead Sciences offers relative stability. |
BusinessWeek
June 13, 2005 |
Biotech's "Fantastic Future Ahead" Some bold predictions on what's coming for the biotech industry from Ernst & Young's Scott Morrison. |
Bio-IT World
July 11, 2002
Mike Fitzgerald |
Funding the Future Investor G. Steven Burrill, CEO of Burrill & Company, helps biotech companies fulfill their potential. He talked recently about his view of the bio-IT field. |
IndustryWeek
October 8, 2003
John S. McClenahen |
Manufacturing Measure Rebounds Sharply At 68% in September, the Manufacturers Alliance/MAPI index signals near-term increase in output. |
Bio-IT World
Jul/Aug 2006
John Russell |
Burrill's Biotech 2006 G. Steven Burrill's Biotech 2006 -- Life Sciences: A Changing Prescription is his 20th annual report on the industry. This longtime market watcher and biotech investment banker has pulled together a kind of whirlwind tour of biotech finances, markets, and technologies. |
IndustryWeek
October 9, 2002
Jill Jusko |
Manufacturing Index Slightly Down But Not Out Manufacturers Alliance/MAPI quarterly measure of future business activity dips, but shows bullish outlook for orders in 2003. |
Bio-IT World
November 2005
G. Steven Burrill |
Biotech Posts Strong Third Quarter Despite overall subpar numbers in September, as compared with the previous four months, this was another excellent quarter for biotech... A good quarter for collaborations... IPO windows open slowly... Biotech still attractive for big pharmaceuticals... |
IndustryWeek
July 9, 2003
John S. McClenahen |
Manufacturing Index Retreats Slightly Despite the dip, Manufacturers Alliance/MAPI's quarterly measure of future business activity signals increased manufacturing output between now and year's end. |
The Motley Fool
March 26, 2004
Charly Travers |
Human Genome Getting on Track What a novel concept for a drug company to focus on commercializing drugs. |
The Motley Fool
April 4, 2009
Brian Orelli |
The Wrong Way to Invest in the Right Stocks Exchange-traded funds don't work for this industry. |
BusinessWeek
May 28, 2009
Catherine Arnst |
Make-or-Break Time for Cancer Drugs Strong presentations at the key oncology conference in late May will be crucial for struggling biotechs. |
Bio-IT World
February 2006
G. Steven Burrill |
Outlook for '06, Look Back at '05 Overall, 2005 turned out to be an exceptional year for the biotech industry, but it wasn't all good news: Look Back at 2005... Predictions for 2006... |
The Motley Fool
April 8, 2004
Charly Travers |
Indevus' Big Score (Maybe) A small biotech company lands a potentially rich deal. |
Global Services
August 27, 2007
Imrana Khan |
Global Services Provider Index The Global Services Provider stock index saw a decline of 9 percent. |
The Motley Fool
August 17, 2004
Charly Travers |
Surviving Biotech's Downturns Advice on withstanding the volatility of the biotech sector. |
BusinessWeek
January 12, 2004 |
Biotech: A Comeback "Balanced On A Razor's Edge" Skeptical investors want to see products that get to market and add to the bottom line. |
Bio-IT World
June 15, 2003
Bob Violino |
Northeast Region Massachusetts: University and Research Hub... Connecticut: Investing in Bio Facilities... New York: Biotech Empire State... New Jersey: Still Big Pharma Country... Pennsylvania: Life Sciences, a Keystone Industry |
The Motley Fool
May 5, 2009
Brian Orelli |
The Wrong Way to Invest in the Right Stocks Persuading you to invest in biotechs should be easy. Persuading you not to use what seems like a less-risky strategy might be harder. Exchange-traded funds just don't work for this industry. |
The Motley Fool
February 9, 2007 |
Affable Affymetrix: Fool by Numbers The biotech company released fourth-quarter 2006 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
IndustryWeek
October 6, 2004
John S. McClenahen |
Manufacturers Alliance Index Eases Off Record Pace U.S. manufacturing's recovery from the 2001 recession is likely to continue during the next three to six months, but at a somewhat slower pace than has recently occurred. But data suggest broad-based expansion is likely to continue. |
Bio-IT World
April 2006
Laura Huckabee-Jennings |
Southern Emergence Why Huntsville, Alabama, will be the next biotech hotbed. |
The Motley Fool
April 18, 2006
Tom Taulli |
An ETF for New Stocks IPOs become the latest to join the ETF party. The IPOX-100 Index Fund is essentially a mid-cap index -- with a nice marketing angle. |
The Motley Fool
April 18, 2007
Selena Maranjian |
Oh, Boy! A New China Index! If you want to invest in China, here comes a new way to do so. The Nasdaq Stock Market thinks that what the world needs now is a new "Nasdaq China Index." |
The Motley Fool
November 4, 2005
Stephen D. Simpson |
A $99 Biotech Portfolio Can this biotech six-pack pay off for aggressive investors? Acadia Pharmaceuticals... Alexion Pharmaceuticals... Arena Pharmaceuticals... Crucell NV... DOV Pharmaceutical... Millennium Pharmaceuticals... |
IndustryWeek
January 12, 2005
John S. McClenahen |
Manufacturers Alliance Outlook Index Dips Again But the alliance's latest manufacturing index figure seems consistent with forecasts that U.S. economic growth will be relatively strong in 2005, although not as strong as in 2004. |
IndustryWeek
October 10, 2001
John S. McClenahen |
Manufacturing Business Outlook Shows Continuing Contraction However, survey suggests makings of manufacturing recovery exist, reports Manufacturers Alliance/MAPI... |
BusinessWeek
November 10, 2003
Arlene Weintraub |
Biotech Startups: Take Your Time Until products are close to approval, the public shouldn't share the risk |
IndustryWeek
July 10, 2002
John S. McClenahen |
Manufacturing Index Surges To Two-Year High Manufacturers Alliance/MAPI's quarterly measure of coming business activity delivers evidence of a strong rebound from last year's depressed levels. |
InternetNews
July 26, 2004
Paul Shread |
Technical Analysis: The Chips Hang On But the Nasdaq loses another support level. |
The Motley Fool
December 31, 2007
Brian Lawler |
The Biotech Year in Review Following the biotech sector is never dull, and 2007 was no exception to the rule. Let's take a look at the highlights and lowlights of 2007. |
| Knowledge@Wharton |
A New Approach to Valuing Biotech Stocks Enormous swings in biotechnology stock prices during the last few weeks show how difficult it is for investors to value biotech companies. It's important to understand the invisible potential locked up in the organizational structure of biotechnology companies... |
The Motley Fool
April 6, 2011
MIchael Johnston |
AAPL Weighting in QQQ to Be Slashed What does the change mean for the ETF? |
The Motley Fool
October 23, 2006
Jack Uldrich |
Is Microsoft on Drugs? If the company uses its new BioIT Alliance not simply to push its existing software, but also to better understand what biotech customers need and want, Microsoft's new drug habit could even provide its long-suffering shareholders a little high. |
